In addition, drugs that enhance the killing action of T cells on tumor cells (ipilimumab (targeting cytotoxic T lymphocyte-associated antigen-4(CTLA4)), pembrolizumab and nivolumab (targeting PD1)) have been approved for the treatment of certain solid tumors (39, 40). This evidence concerns the gene CTLA4 and neoplasm.